Applied Therapeutics, Inc. (APLT)
NASDAQ: APLT · Real-Time Price · USD
1.140
-0.080 (-6.56%)
Oct 30, 2025, 10:02 AM EDT - Market open
Applied Therapeutics Revenue
Applied Therapeutics had revenue of $121.00K in the twelve months ending June 30, 2025, down -136.34% year-over-year. In the year 2024, Applied Therapeutics had annual revenue of $455.00K, down -95.45%.
Revenue (ttm)
$121.00K
Revenue Growth
-136.34%
P/S Ratio
1,483.92
Revenue / Employee
$3,457
Employees
35
Market Cap
164.17M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 455.00K | -9.54M | -95.45% |
| Dec 31, 2023 | 9.99M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
APLT News
- 1 day ago - Halper Sadeh LLC Encourages Applied Therapeutics, Inc. Shareholders to Contact the Firm to Discuss Their Rights - Business Wire
- 4 weeks ago - Applied Therapeutics Provides Update Following Meeting with FDA - GlobeNewsWire
- 2 months ago - Applied Therapeutics Reports Second Quarter 2025 Financial Results - GlobeNewsWire
- 4 months ago - Applied Therapeutics Announces Key Leadership Appointments - GlobeNewsWire
- 5 months ago - Applied Therapeutics Presents Full 12-Month Clinical Results and New Topline Data from INSPIRE Phase 2/3 Trial of Govorestat in CMT-SORD in Late-Breaking Oral Presentation at the Peripheral Nerve Society 2025 Annual Meeting - GlobeNewsWire
- 6 months ago - Applied Therapeutics Reports First Quarter 2025 Financial Results - GlobeNewsWire
- 6 months ago - Applied Therapeutics Announces Acceptance of Late-Breaking Abstract for Oral Presentation at the Peripheral Nerve Society 2025 Annual Meeting - GlobeNewsWire
- 7 months ago - Applied Therapeutics Files Form 12b-25 with the Securities and Exchange Commission - GlobeNewsWire